| Exviera (dasabuvir) / AbbVie |
2016-003607-59: An Open-Label Study to Evaluate Long-Term Results With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) on ovarian function in fertile women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection. Studio in aperto per valutare i risultati a lungo termine con Ombitasvir-paritaprevir-Ritonavir e Dasabuvir, con o senza ribavirina (RBV) sulla funzione ovarica delle donne in et¿ fertile con epatite cronica HCV-positiva, genotipo 1 e 4 . |
|
|
| Not yet recruiting | 4 | 50 | Europe | VIEKIRAX, EXVIERA, 043841, Film-coated tablet, VIEKIRAX - 12,5MG/75MG/50MG COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PE/PCTFE/ALU) - 56 COMPRESSE (CONFEZIONE MULTIPLA), EXVIERA - 250 MG COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PE/PCTFE/ALU) - 56 COMPRESSE (CONFEZIONE MULTIPLA) | DIPARTIMENTO AD ATTIVITà INTEGRATA CHIRURGICO, MEDICO, ODONTOIATRICO E DI SCIENZE MORFOLOGICHE, ABBVIE SRL | Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection Epatite cronica HCV-positiva, genotipo 1 e 4, Hepatitis C EPATITE C, Diseases [C] - Virus Diseases [C02] | | | | |
NCT02460133: Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment |
|
|
| Active, not recruiting | 4 | 44 | NA | Paritaprevir, Ritonavir, Dasabuvir, Ombitasvir, Ribavirin | Nova Scotia Health Authority, Provincial Correction Centre (PEI) | Hepatitis C Virus | 10/25 | 10/25 | | |
2014-002962-57: Hepatitis C meggyógyítása, cryoglobunaemia és szövödményeinek (vaculitis, neuritis) megszüntetése |
|
|
| Ongoing | 3 | 1 | Europe | ABT-450/r/ABT-267; ABT333 | Egyesített Szent István és Szent László Kórház - Rendelőintézet | | | | | |
2014-004111-37: Individual Patient Access to AbbVie ABT-450/rítonavir/ABT-267 and ABT333 Coadministered witb Ribavirín (RBV) in Patient with Genotype 1 Hepatitis C VírusInfection witb Cirrhosis |
|
|
| Ongoing | 3 | 1 | Europe | ABT-450/r/ABT-267+ABT-333 | BUDAI HEPATOLÓGIAI CENTRUM | | | | | |
2014-004268-38: Individual Patient Access to AbbVie ABT-450/ritopnavir/ABT-267 and ABT-333 Coadministeres with ribavirin (RBV) in Adult Liver Transplant Recipient with Genotype 1 Hepatitis C Virus Infection |
|
|
| Ongoing | 3 | 1 | Europe | ABT-450/ritonavir/ABT-267, ABT-333, | Semmelweis Egyetem Transzplantációs és Sebészeti Klinika | | | | | |
| Ongoing | 2 | 408 | Europe | Viekirax, Exviera (Dasabuvir), Harvoni, Ribavirin (film-coated 200mg), Ribavirin (hard capsule, 200mg), Ribavirin (film-coated, 400mg), Maviret, Film-coated tablet, , Viekirax, Exviera (Dasabuvir), Harvoni, Maviret | Imperial College London, NIHR Efficacy and Mechanism Evaluation Programme | Hepatitis C Infection (HCV) (genotype 1a/1b/4), Hepatitis C infection, Diseases [C] - Virus Diseases [C02] | | | | |
C-DIAMOND, NCT04952207: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C |
|
|
| Recruiting | N/A | 300 | RoW | Direct-acting antiviral agents, daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir, sofosbuvir, velpatasvir, ledipasvir, elbasvir, grazoprevir, danoprevir, glecaprevir, pibrentasvir, voxilaprevir | Qing XIe, Gilead Sciences, Tigermed Consulting Co., Ltd | Hepatitis C, Chronic | 07/21 | 08/21 | | |
| ALS-2158 / J&J, Vertex |
ACTRN12612000176864: A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-002158 to Evaluate the Safety, Tolerability and Pharmacokinetics of
Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects with Chronic Hepatitis C Genotype 1 Infection. |
|
|
| Recruiting | 1 | 78 | | | CPR Pharma Services, Alios BioPharma Inc | Chronic Hepatitis C infection | | | | |
| Sovaldi (sofosbuvir) / Gilead |
ACTRN12620000794909: An efficacy study of combined oral doses of glecaprevir/pibrentasvir and sofosbuvir for 16 weeks in hepatitis C patients with documented NS5A resistance who did not respond to previous treatment |
|
|
| Not yet recruiting | 4 | 75 | | | Auckland District Health Board, Auckland District Health Board | Hepatitis C | | | | |
2014-004134-26: A multicenter prospective study on the cost / benefit / safety of Sofosbuvir administered to patients with chronic hepatitis C virus and Mixed Cryoglobulinemia Studio prospettico a cui aderiscono più centri che valuta i costi/benefici/sicurezza del farmaco Sofosbuvir somministrato a pazienti affetti da epatite cronica da virus C e Crioglobulinemia Mista |
|
|
| Ongoing | 4 | 30 | Europe | Tablet, Sovaldi | Centro Masve -Università degli Studi di Firenze-AOUC, Gilead Sciences Int, Ltd. | HCV chronic hepatitis and Mixed Cryoglobulinemia Epatite cronica HCV correlata e Sindrome Crioglobulinemica, Patients with chronic hepatitis by hepatitis virus C and mixed cryoglobulinemia Paziente affetto da epatite cronica da virus C e crioglubulinemia mista, Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR1900023342: A phase IV Study to Evaluate the Safety and Effectiveness of Sofosbuvir-containing Treatment Regimens in Patients with Chronic Hepatitis C Virus (HCV) Infection in a Chinese Real-World Setting |
|
|
| Recruiting | 4 | 3000 | | Case series | Beijing Tsinghua Changgung Hospital; Gilead Sciences Shanghai Pharmaceutical Technology., Ltd, Gilead Sciences Shanghai Pharmaceutical Technology.,Ltd | HCV | | | | |
STRIVE-4, NCT03855917: Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir |
|
|
| Recruiting | 4 | 30 | RoW | Sofosbuvir 400mg [Sovaldi], Sovaldi, Glecaprevir/pibrentasvir (300mg/120mg), Maviret | Kirby Institute | Hepatitis C | 02/26 | 02/26 | | |
NCT03444272: Effect of Direct-acting Antiviral Drugs on Erectile Function |
|
|
| Recruiting | 3 | 105 | RoW | Sofosbuvir and Daklatasuvir, Sofaldy, mpiviropack, daklanork | Sherief Abd-Elsalam, Benha University | Hepatitis C | 12/22 | 12/22 | | |
NCT04497649: Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients |
|
|
| Recruiting | 2/3 | 100 | RoW | Sofosbuvir, Mpiviropack, Sovaldy, soflanork, Daclatasvir, daklinza, daklanork | Tanta University | Covid19 | 04/21 | 04/21 | | |
| Recruiting | 2/3 | 60 | RoW | sofosbuvir, Mpiviropack, Sovaldy, soflanork, Sofosbuvir ledipsavir, mpiviropack plus, Daclatasvir, daklinza | Tanta University | COVID | 08/21 | 08/21 | | |
| Completed | 2/3 | 256 | RoW | Atazanavir, Active Group, Daclatasvir 60 mg, Sofusbuvir + Daclastavir 60 mg, Placebo Atazanavir, Placebo group, Placebo Daclatasvir 60 mg, Placebo Sofusbuvir + Daclatasvir 60 mg | Hospital do Coracao | COVID-19 | 08/21 | 08/21 | | |
NCT04885855: 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C |
|
|
| Recruiting | 2/3 | 316 | RoW | Sofosbuvir 400 MG, Grateziano, Ravidasvir 200mg, PPI-668 | Muhammad Radzi Abu Hassan | Hepatitis C | 10/22 | 12/22 | | |
IRCT20200328046882N1: Efficacy and safety of Sofosbuvir in the treatment of SARS-CoV-2: An Open Label phase II Trial |
|
|
| Recruiting | 2 | 0 | Tehran | Sovaldi (sofosbuvir) - Gilead | Gilead | SARS-CoV-2 َassociated SARI | | | | |
2018-003640-23: PHASE II CLINICAL STUDY ON THE USE OF HCV+ DONORS FOR SOLID ORGAN TRANSPLANTATION. STUDIO CLINICO DI FASE II PER L'UTILIZZO DI DONATORI HCV+ A SCOPO DI TRAPIANTO. |
|
|
| Ongoing | 2 | 212 | Europe | EPCLUSA SOFOSBUVIR 400MG/VELPATASVIR 100MG, [1BV30D], Film-coated tablet, EPCLUSA | ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE - ISMETT | USE OF POSITIVE DONORS FOR INFECTION OF THE HEPATITIS VIRUS FOR THE TRANSPLANTATION OF SOLID ORGANS IN AN ENDEMIC AREA FOR HEPATITIS C WITH LOW RATE OF DONATIONS FROM CADAVERS: OPEN PHASE II CLINICAL STUDY. UTILIZZO DI DONATORI POSITIVI PER INFEZIONE DEL VIRUS DELL’EPATITE C PER IL TRAPIANTO DI ORGANI SOLIDI IN UN’AREA ENDEMICA PER EPATITE C CON BASSO TASSO DI DONAZIONI DA CADAVERE: STUDIO CLINICO MONOCENTRICO APERTO DI FASE II., HCV- patient to whom an organ from a HCV+ donor is transplanted who will receive Epclusa. Pazienti HCV- a cui venga trapiantato un organo da donatore HCV+ che verranno trattati con Epclusa., Diseases [C] - Digestive System Diseases [C06] | | | | |
ChiCTR1800017298: Pharmacokinetics study of sofosbuvir tablets in healthy Chinese subjects |
|
|
| Recruiting | 1 | 48 | | After the subjects were fasted for at least 10 h, each group received a low dose (400 mg, 1 tablet) ;After the subjects were fasted for at least 10 h, each group fed a low-dose oral dose (400 mg, 1 tablet) ;After the subjects were fasted for at least 10 h, each group received a high dose (800 mg, 2 tablets) ;Continuous administration for 8 days, low dose (400 mg) on an empty stomach every morning | The Third Hospital of Changsha; Nanjing ChiaTai TianQing Pharmaceuticals LP, self-raised | Chronic hepatitis C. | | | | |
| Recruiting | N/A | 96 | | sofosbuvir tablet administered once under fasting condition, 400 mg ;sofosbuvir tablet (Gilead) administered once under fasting condition, 400 mg ;sofosbuvir tablet administered once under fed condition, 400 mg ;sofosbuvir tablet (Gilead) administered once under fed condition, 400 mg | the Third Hospital of Changsha; Nanjing ChiaTai TianQing Pharmaceuticals LP, self-raised | Chronic hepatitis C. | | | | |
| Recruiting | N/A | 104 | | Fasting test preparations Sofosbuvir tablets(1dose, 400 mg) ;Fasting to Reference Preparation Sofosbuvir (1 dose, 400 mg) ;Postprandial test preparation of sofbuvir tablets (1 dose, 400mg) ;Postprandial reference preparation of soflobuvir(1 dose, 400 mg) | The Third Hospital of Changsha; Nanjing ChiaTai TianQing Pharmaceuticals LP, self-raised | Chronic hepatitis C | | | | |
SCALE-C, NCT03776760: Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination |
|
|
| Recruiting | N/A | 600 | RoW | Fingerstick GeneXpert HCV RNA quantitative assay, sofosbuvir/velpatesvir, Epclusa, glecaprevir/pibrentasvir, Maviret | Kirby Institute, South Australian Health and Medical Research Institute, Flinders University | Hepatitis C, Hepatitis, Liver Diseases, Hepatitis, Viral, Human, RNA Virus Infections, Digestive System Diseases | 08/22 | 08/22 | | |
| Recruiting | N/A | 200 | RoW | Observation only | Kaohsiung Medical University Chung-Ho Memorial Hospital, Chang Gung Memorial Hospital, National Taiwan University Hospital, National Cheng-Kung University Hospital, Chi Mei Medical Hospital, China Medical University, China, Mackay Memorial Hospital, Taipei Veterans General Hospital, Taiwan, Changhua Christian Hospital, Pusan National University Hospital, Asan Medical Center, Korea University, Inje University, Korea University Guro Hospital, Kyungpook National University Hospital, Seoul National University Hospital, Severance Hospital, Samsung Medical Center, Seoul National University Bundang Hospital, Soon Chun Hyang University, Seoul St. Mary's Hospital, Gachon University Gil Medical Center, Dong-A University Hospital, Gangnam Severance Hospital | Liver Fibroses, HepatoCellular Carcinoma, Cryoglobulinemia, Metabolic Disease, Diabetes Mellitus | 09/22 | 09/22 | | |
NCT04122066: the Pulmonary Safety of Antihepatitis C Treatment |
|
|
| Not yet recruiting | N/A | 50 | NA | sofosbuvir \daclatsvir, Sovaldi\Daklinza | Assiut University | Hepatitis C | 12/22 | 12/23 | | |
TOPIC, NCT03981211: Treatment of HOsPitalised Inpatients for Hepatitis C (): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs |
|
|
| Recruiting | N/A | 60 | RoW | Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet, Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet | Kirby Institute | Hepatitis C, Liver Inflammation, Liver Cirrhoses | 02/25 | 02/25 | | |
| Not yet recruiting | N/A | 1000 | NA | Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa], Epclusa | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Gilead Sciences | Hepatitis C in Substance Users | 08/23 | 05/24 | | |
NCT05248919: Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan |
|
|
| Enrolling by invitation | N/A | 318 | RoW | Epclusa (nucleotide HCV NS5B polymerase inhibitors)., Sofosbuvir 400 Mg and Velpatasvir 100 Mg Oral Capsules | Queen Mary University of London, Aga Khan University, Dow University of Health Sciences, University of Oxford, University of Bristol | Hepatitis C | 09/25 | 09/25 | | |
ChiCTR2400088566: To evaluate colopivir hydrochloride capsules in combination with sofosbuvir tablets for the treatment of chronic HCV in the real world Safety and efficacy studies in infected patients |
|
|
| Not yet recruiting | N/A | 100 | | Oral antiviral | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Beijing Keyingling Biotechnology Co., LTD | Patients with chronic HCV infection with or without cirrhosis | | | | |
NCT05601518: Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study. |
|
|
| Not yet recruiting | N/A | 450 | RoW | | Beijing Tsinghua Chang Gung Hospital | Hepatitis C Infection | 12/23 | 12/23 | | |
| ledipasvir/sofosbuvir / Generic mfg. |
2015-003024-31: Protecting immune responses in patients treated with the new DAA anti hepatitis C alone or in combination with previously used medications (interferon and ribavirin) Risposte immunitarie proteggenti in pazienti trattati con i nuovi farmaci anti epatite C (nuovi DAA) da soli o in associazione con i farmaci precedentemente utilizzati (interferone e ribavirina) |
|
|
| Not yet recruiting | 4 | 30 | Europe | PEGINTERFERONE ALFA-2A, RIBAVIRINA, SOFOSBUVIR, LEDIPASVIR+SOFOSBUVIR, N.A., Solution for injection, Capsule, hard, Film-coated tablet, PEGASYS - 180MCG-SOLUZ. INIETTABILE-USO SOTTOCUT.-PENNA PRERIEMPITA-0.5 ML (360MCG/ML) 1 PENNA PRERIEMPITA, REBETOL - 200 MG 84 CAPSULE RIGIDE IN BLISTER, SOVALDI - 400 MG - COMPRESSA RIVESTITA CON FILM - FLACONE (HDPE) - 28 COMPRESSE, HARVONI - 90 MG/400 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - FLACONE (HDPE) - 28 COMPRESSE RIVESTITE CON FILM | AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA, GILEAD SCIENCES SRL | CHRONIC HEPATITIS C EPATITE C CRONICA, CHRONIC HEPATITIS C EPATITE C CRONICA, Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR-OPC-16008158: Safety and efficacy of sofosbuvir plus ledipasvir for Chinese hepatitis C patients |
|
|
| Recruiting | 4 | 100 | | sofosbuvir, ledipasvir and ribavirin ;sofosbuvir, ledipasvir and ribavirin ;sofosbuvir, ledipasvir | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Key Scientific Research Project of Henan Higher Education Institutions of China (No. 15A320083) | Chronic hepatitis C | | | | |
NCT03402165: Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C |
|
|
| Recruiting | 4 | 1200 | RoW | Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir, Sofaldy, Harvony | Sherief Abd-Elsalam | Hepatitis C | 12/22 | 12/22 | | |
CHROME, NCT03823911: Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication |
|
|
| Completed | 4 | 87 | US | Elbasvir / Grazoprevir Oral Tablet [Zepatier], Sofosbuvir/Ledipasvir, Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir, Sofosbuvir/Velpatasvir/Voxilaprevir, Cardiac MRI | University of Maryland, Baltimore, National Institutes of Health (NIH), Merck Sharp & Dohme LLC | Cardiovascular Diseases, Hepatitis C, Hiv | 12/22 | 12/22 | | |
| Recruiting | 3 | 0 | Tehran | Cimivir-L (ledipasvir/sofosbuvir) - Gilead, Tehran University of Medical Sciences | Gilead, Tehran University of Medical Sciences | | | | | |
2016-002958-21: Study HCV-art: An Open-Label, pilot Study, to Explore the Clinical Safety and Efficacy of Sofosbuvir/Ledipasvir in Hepatitis C Virus (HCV) Chronic Patients with Arthritis Studio pilota, monocentrico, in aperto, per valutare sicurezza ed efficacia della combinazione sofosbuvir/ledipasvir in pazienti con epatite C cronica, genotipo 1, affetti da artrite cronica |
|
|
| Not yet recruiting | 3 | 50 | Europe | HARVONI, RIBAVIRINA, J05AX65, RIBAVIRINA, Film-coated tablet, Capsule, hard, HARVONI - 90 MG/400 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - FLACONE (HDPE) - 28 COMPRESSE RIVESTITE CON FILM, REBETOL - 200 MG 84 CAPSULE RIGIDE IN BLISTER | AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI, Gilead | Chronic HCV associated with chronic arthritis. HCV cronica associata ad artrite cronica., Chronic HCV associated with chronic arthritis. HCV cronica associata ad artrite cronica., Diseases [C] - Virus Diseases [C02] | | | | |
NCT04353986: PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders |
|
|
| Recruiting | 3 | 24 | RoW | Sofosbuvir and Ledipasvir, SOF/LED | Ain Shams University | HCV Infection, Beta Thalassemia Major | 04/23 | 12/23 | | |
2013-002296-17: An international study to assess the safety and efficacy of a combination of new investigational drugs in patients with chronic hepatitis C virus infection who have previously failed treatment. |
|
|
| Not yet recruiting | 2 | 150 | Europe | Sofosbuvir/GS-5885 FDC, Ribasphere, GS-7977/GS-5885 FDC, Film-coated tablet, Ribasphere Tablets | Gilead Sciences, Inc., Gilead Sciences Inc | Chronic Genotype 1 Hepatitis C Virus Infection Adultes présentant une infection chronique par le virus de l’hépatite C (VHC) de génotype 1 et une cirrhose, et précédemment traités par un inhibiteur de protéase avec PEG+RBV., Hepatitis C Virus Infection Infection chronique par le virus de l'hépatite C de génotype 1 (correspondant à une variété du virus) chez des patients ayant déjà reçu un traitement pour cette maladie., Diseases [C] - Virus Diseases [C02] | | | | |
2013-003978-27: A study to assess the safety and efficacy of a combination of Sofosbuvir/Ledipasvir in patients with Chronic Genotype 4 or 5 hepatitis C Infection. |
|
|
| Not yet recruiting | 2 | 80 | Europe | SOF/LDV FDC, GS-7977/GS-5885 FDC, Film-coated tablet | Gilead Sciences, Inc., Gilead Sciences Inc | Chronic Genotype 4 and Genotype 5 Hepatitis C Virus Infection, Hepatitis C Virus Infection, Diseases [C] - Virus Diseases [C02] | | | | |
2015-002401-10: Pilot multicenter open label study on treatment with Sofosbuvir/Ledipasvir FDC for patients with thalassemia major and HCV infection. Studio pilota multicentrico con LDV/SOF in pazienti con talassemia major e infezione cronica da HCV |
|
|
| Ongoing | 2 | 100 | Europe | HARVONI, 700016355, Film-coated tablet, HARVONI - 90 MG/400 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - FLACONE (HDPE) - 28 COMPRESSE RIVESTITE CON FILM | FONDAZIONE CASA SOLLIEVO DELLA SOFFERENZA OPERA DI SAN PIO DA PIETRELCINA OSPEDALE IRCCS, IRCCS CASA SOLLIEVO DELLA SOFFERENZA | Patients with thalassemia major and HCV infection either naïve or on nucleo(s)tide analogs treatment, data on Sofosbuvir-based treatment are currently lacking, while, due to the long infection duration, this category of patients has a urgent treatment need. Pazienti con talassemia major e infezione cronica da HCV di genotipo ¼ (naïve o precedentemente trattati senza successo), Patients with thalassemia major and HCV infection either naïve or on nucleo(s)tide analogs treatment, data on Sofosbuvir-based treatment are currently lacking, while, due to the long infection duratio Pazienti con talassemia major e infezione cronica da HCV di genotipo ¼ (naïve o precedentemente trattati senza successo), Diseases [C] - Virus Diseases [C02] | | | | |
| Completed | 2 | 40 | Europe | Ledipasvir+Sofosbuvir, Harvoni, Sofosbuvir+Velpatasvir, Epclusa | Fondazione Italiana Linfomi ONLUS | Indolent B-cell Lymphoma, Hepatitis C | 02/20 | 11/22 | | |
| Recruiting | 2 | 160 | RoW | PR4 + LDV/SOF + ASV 4 wk, Pegasys®, Copegus®, Harvoni®, Sunvepra®, PR4 + LDV/SOF + SMV 4 wk, OLYSIO®, PR4 + LDV/SOF + ASV 6 wk, PR4 + LDV/SOF + SMV 6 wk, PR4 + LDV/SOF + ASV 8 wk, PR4 + LDV/SOF + SMV 8 wk, PR4 + LDV/SOF + ASV 12 wk, PR4 + LDV/SOF + SMV 12 wk | Humanity and Health Research Centre, Beijing 302 Hospital, Nanfang Hospital of Southern Medical University | Chronic Hepatitis C Infection | 10/22 | 12/22 | | |
NCT03903185: Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy |
|
|
| Completed | 1/2 | 24 | RoW | Ledipasvir / Sofosbuvir Oral Product, LDV\SOF | Ain Shams University, Cairo University | Hepatitis C, Chronic, Hematologic Malignancy | 07/23 | 08/23 | | |
| Recruiting | N/A | 300 | Europe | Elbasvir / Grazoprevir Oral Tablet, sofosbuvir, ledipasvir | University Hospital, Akershus | Hepatitis C, Substance Use Disorders | 10/19 | 12/22 | | |
| sofosbuvir/velpatasvir / Generic mfg. |
2016-000599-87: Treatment for type 3 chronic hepatitis C virus infection: comparing 12 and 24 weeks of antiviral drugs - is longer therapy worthwhile? |
|
|
| Ongoing | 4 | 60 | Europe | Epclusa, Film-coated tablet, Epclusa | Queen Mary University of London, National Institute for Health Research | Adult patients chronically infected with genotype 3 hepatitis C virus with cirrhosis, Adults infected with hepatitis C virus (subtype 3) causing severe liver scaring and damage, Diseases [C] - Virus Diseases [C02] | | | | |
2016-003941-27: Epclusa blood concentrations after crushing the tablet compared to the whole tablet. |
|
|
| Ongoing | 4 | 14 | Europe | Tablet, Epclusa | Radboud University Medical Center, Radboud University Medical Center | hepatitis C virus, hepatitis C virus, Diseases [C] - Virus Diseases [C02] | | | | |
2017-001024-21: treatment of eradication of HCV infection in immigrant patients with innovative drug Trattamento di eradicazione dell'infezione da HCV in pazienti immigrati con farmaco innovativo |
|
|
| Ongoing | 4 | 6000 | Europe | EPCLUSA, 044928012, Coated tablet, EPCLUSA | A.O.U. Università degli Studi della Campania "Luigi Vanvitelli", Gilead Scinces, GILEAD SCIENCES | Chronic HCV hepatitis, all fibrosis epatite cronica da HCV, tutte le fibrosi, hepatitis C virus infection infezione da virus dell'epatite C, Diseases [C] - Virus Diseases [C02] | | | | |
2020-003879-18: Treatment of chronic hepatitis C in children aged 6 – 18 years using a direct-acting antiviral (sofosbuvir/velpatasvir) acting against all HCV genotypes Leczenie dzieci w wieku 6 – 18 lat z przewlekłym wirusowym zapaleniem wątroby typu C przy użyciu leku o bezpośrednim działaniu przeciwwirusowym działającego na wszystkie genotypy wirusa HCV |
|
|
| Not yet recruiting | 4 | 50 | Europe | Epclusa (sofosbuvir/velpatasvir), Epclusa sofosbuvir/velpatasvir), Tablet, Epclusa (Sofosbuvir/Velpatasvir) | Medical University of Warsaw, Medical Research Agency | Chronic hepatitis C Przewlekłe wirusowe zapalenie wątroby typu C, Chronic hepatitis C caused by hepatitis C virus (HCV) infection Przewlekłe wirusowe zapalenie wątroby typu C wywołane przez wirus HCV, Diseases [C] - Virus Diseases [C02] | | | | |
ACTRN12618001939280: Sofosbuvir/Velpatasvir and Mental Health Impact in people with Lived Experience and Hepatitis C infection - SMILE-C Trial |
|
|
| Terminated | 4 | 150 | | | The University of Adelaide, Gilead Sciences, Inc. | Hepatitis C virus infection, Schizophrenia, Schizoaffective disorder, Bipolar disorder, Cognitive dysfunction | | | | |
NCT06306300: Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil) |
|
|
| Recruiting | 4 | 30000 | RoW | Specialist - Epclusa 400Mg-100Mg Tablet, Standard-of-Care (SC) HCV treatment, Non- specialist - Epclusa 400Mg-100Mg Tablet, Simplified-and-Decentralized (SD) HCV treatment | Oswaldo Cruz Foundation, Conselho Nacional de Desenvolvimento Científico e Tecnológico | Hepatitis C | 12/25 | 12/25 | | |
NCT05264558: Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30% |
|
|
| Completed | 4 | 606 | RoW | Xpert HCV Viral load finger stick point of care test (Cepheid), Epclusa 400Mg-100Mg Tablet, Standard of care | Macfarlane Burnet Institute for Medical Research and Public Health Ltd, Cairns Hinterland Health Hospital and Health Services, The University of Queensland | Hepatitis C | 08/23 | 09/23 | | |
NCT05016609: Same-visit Hepatitis C Testing and Treatment (The QuickStart Study) |
|
|
| Recruiting | 4 | 1800 | RoW | OraQuick HCV Antibody test (OraSure Technologies, Inc), Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid), Sofosbuvir/Velpatasvir (Gilead) | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | Hepatitis C | 04/24 | 06/24 | | |
| Recruiting | 4 | 148 | US | Sofosbuvir/velpatasvir, Epclusa, Monitoring, Sofosbuvir/velpatasvir (Epclusa) | Brigham and Women's Hospital | Hepatitis C, Awaiting Organ Transplant | 12/23 | 12/23 | | |
BDTAF, NCT04997564: The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China |
|
|
| Recruiting | 4 | 120 | RoW | Tenofovir Alafenamide 25 MG, Sofosbuvir / Velpatasvir | Peking University First Hospital | Chronic Hepatitis C, Chronic Hepatitis B | 12/23 | 12/23 | | |
| Recruiting | 4 | 100 | Canada, US | Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet, Epclusa | Catherine Anne Chappell, Gilead Sciences | Hepatitis C, Chronic, Pregnancy; Infection | 06/25 | 12/25 | | |
| Active, not recruiting | 4 | 374 | US | Sofosbuvir/velpatasvir (Epclusa®) | Jennifer Havens, National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), Gilead Sciences, University of Kentucky, Icahn School of Medicine at Mount Sinai, University of Bristol | Hepatitis C, Opioid-Related Disorders, Injection Drug Use | 04/25 | 04/25 | | |
NCT03520660: People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents |
|
|
| Active, not recruiting | 4 | 121 | US | Epclusa | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases | 12/32 | 12/32 | | |
IRCT20130812014333N1: Comparative assessment of the efficacy and safety of add ontreatment with “Sofosbuvir plus Velpatasvir” to “standard of care therapeutic regimen” in patients with COVID-19 |
|
|
| Recruiting | 3 | 80 | Kermanshah | sofosbuvir/velpatasvir - Generic mfg. | Gilead, Generic mfg., Kermanshah University of Medical Sciences | COVID-19 | | | | |
NCT03891550: Micro-elimination of Hepatitis C Virus Infection in Uremics |
|
|
| Active, not recruiting | 3 | 135 | RoW | Epclusa | Kaohsiung Medical University Chung-Ho Memorial Hospital | Hepatitis C | 04/24 | 04/24 | | |
2018-003474-27: Multicenter trial for the treatment of acute Hepatitis C with Sofosbuvir/Velpatasvir |
|
|
| Not yet recruiting | 2 | 20 | Europe | Film-coated tablet, Epclusa® 400 mg/100 mg Filmtabletten | Hannover Medical School, Gilead Sciences, Inc., German Center for Infection Research (DZIF) | Adults with acute hepatitis C virus (HCV) infection, Adults with acute hepatitis C virus infection, Diseases [C] - Virus Diseases [C02] | | | | |
NCT03222531: Expanding the Pool in Orthotopic Heart Transplantation |
|
|
| Active, not recruiting | 2 | 20 | US | sofosbuvir/velpatasvir, Epclusa | Mary E. Keebler, MD | Hepatitis C, Heart Transplant, Cardiac Transplant | 05/25 | 05/25 | | |
TROJAN-C, NCT03383419: Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients |
|
|
| Active, not recruiting | 2 | 15 | US | Epclusa | Baylor Research Institute | Heart Failure | 12/23 | 12/23 | | |
NCT03809533: The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients |
|
|
| Active, not recruiting | 2 | 30 | US | sofosbuvir/velpatasvir, Epclusa | Amit D Tevar, MD, University of Pittsburgh Medical Center | Kidney Transplantation, Hepatitis C | 03/26 | 03/26 | | |
NCT03819322: The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients |
|
|
| Active, not recruiting | 2 | 73 | US | sofosbuvir/velpatasvir, Epclusa | Naudia Jonassaint. MD, University of Pittsburgh Medical Center | Liver Transplant, Hepatitis C | 03/25 | 03/25 | | |
| Active, not recruiting | 2 | 201 | US | Epclusa | University of Pennsylvania, Gilead Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | End Stage Renal Disease | 06/25 | 01/26 | | |
| Completed | 1/2 | 10 | US | Zepatier, Epclusa | University of Pennsylvania, Merck Sharp & Dohme LLC | Lung Diseases | 12/21 | 12/22 | | |
| Active, not recruiting | 1 | 26 | Canada | Sofosbuvir-velpatasvir (400 mg/100 mg), Epclusa, Ex Vivo Lung Perfusion (EVLP), Normothermic EVLP | University Health Network, Toronto, Gilead Sciences | Lung Transplant Infection, Hepatitis C | 01/20 | 12/24 | | |
NCT04382404: Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir |
|
|
| Completed | 1 | 11 | US | Sofosbuvir-Velpatasvir Drug Combination, Epclusa | Catherine Anne Chappell, Gilead Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Hepatitis C, Chronic | 10/23 | 10/23 | | |
| Not yet recruiting | 1 | 3040 | NA | sofosbuvir/velpatasvir (SOF/VEL), Shortened read time of rapid diagnostic test for hepatitis C virus., OraQuick® HCV RDT | Médecins du Monde, UNITAID, Burnet Institute, University of Bristol, International Network of People who Use Drugs | Hepatitis C, RDT | 12/26 | 12/26 | | |
NCT04039698: Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in Brazil |
|
|
| Active, not recruiting | N/A | 144 | RoW | Telemedicine, Velpatasvir/Sofosbuvir, Epclusa | Hospital de Clinicas de Porto Alegre, Ministry of Health, Brazil, State Secretary of Health of Rio Grande do Sul, TelessaúdeRS / UFRGS | Chronic Hepatitis C | 12/20 | 11/21 | | |
ChiCTR1800020246: Study for Antiviral Therapy of Patients Co-infected with HIV and HCV |
|
|
| Not yet recruiting | N/A | 600 | | Epclusa@(Sofosbuvir/ velpatasvir)(po) ;Genvoya@(elvitegravir 150mg/cobicistat150mg/emtricitabine200mg/tenofovir alafenamide10mg)(po) | Guangzhou Eighth People's Hospital; Level of the institution：, The Thirteenth Five-Year Plan National Science and Technology Major Project Sub-study 3 | HIV/HCV Co infactiong | | | | |
ChiCTR1900027793: Two direct antiviral drugs in the clinical effect of reverse c liver fibrosis multicenter prospectie cohort study |
|
|
| Not yet recruiting | N/A | 280 | | Grazoprevir/elbasvir ;Sofosbuvir and velpatasvir | Department of Gastroenterology, Xinqiao Hospital, Affiliated to Military Medical University; Xinqiao Hospital of Army Military University, Self-raised | Chronic hepatitis c | | | | |
| Not yet recruiting | N/A | 100 | NA | sofosbuvir/velpatasvir | Eastern Idaho Public Health | Hepatitis C | 02/25 | 08/25 | | |
NCT04948801: SOF/VEL±RBV: Efficacy and Safety in GT 3 and 6 HCV Patients |
|
|
| Recruiting | N/A | 150 | RoW | Epclusa (sofosbuvir and velpatasvir) | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis C | 12/21 | 12/21 | | |
| Recruiting | N/A | 300 | Canada | Epclusa | Vancouver Infectious Diseases Centre | Hepatitis C, Chronic, Drug Use | 12/23 | 12/24 | | |
| bemnifosbuvir (AT-527) / Atea Pharma |
2022-003268-25: A study to evaluate the efficacy and safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 |
|
|
| Not yet recruiting | 3 | 1500 | Europe | Bemnifosbuvir Hemisulfate, BEM; AT-527, Tablet | Atea Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc. | COVID-19, COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
| Completed | 3 | 2295 | Europe, Canada, Japan, US, RoW | Bemnifosbuvir (BEM), AT-527, Placebo | Atea Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc. | SARS CoV 2 Infection, COVID-19 | 04/24 | 05/24 | | |
2019-001431-31: A Phase 2 Study Assessing the Safety and Efficacy of AT-527 in Combination with Daclatasvir in Subjects with Chronic HCV Infection |
|
|
| Not yet recruiting | 2 | 15 | Europe | Daklinza, AT-527, na, Tablet, Daklinza | Atea Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc. | HCV-Infected subjects, Hepatitis C, Diseases [C] - Virus Diseases [C02] | | | | |
| Active, not recruiting | 2 | 275 | Europe, Canada, US, RoW | Bemnifosbuvir, AT-527, Ruzasvir, AT-038 | Atea Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc. | Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis, HCV | 11/24 | 11/24 | | |
2019-004997-24: A Phase I/IIa Study Assessing AT-777 in Healthy Subjects and AT-777 in Combination with AT-527 in HCV-Infected Subjects |
|
|
| Not yet recruiting | 1/2 | 44 | Europe | AT-527, AT-777, Tablet, Capsule | Atea Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc. | HCV-Infected subjects, Hepatitis C, Diseases [C] - Virus Diseases [C02] | | | | |
| Completed | 1 | 32 | Canada | Cohort 1 BEM + Ruzasvir, AT-527, Cohort 2 Ruzasvir + BEM | Atea Pharmaceuticals, Inc. | Healthy Volunteer Study | 03/23 | 03/23 | | |
NCT05905497: The Study of Bemnifosbuvir in Healthy Japanese Subjects |
|
|
| Completed | 1 | 14 | US | Bemnifosbuvir (BEM), AT-527 | Atea Pharmaceuticals, Inc. | Healthy Volunteer Study | 05/23 | 05/23 | | |
NCT05905484: Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects |
|
|
| Completed | 1 | 35 | Canada | Bemnifosbuvir (BEM), AT-527, Placebo, Moxifloxacin | Atea Pharmaceuticals, Inc. | Healthy Volunteer Study | 05/23 | 05/23 | | |
NCT05724693: Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function |
|
|
| Completed | 1 | 39 | US | Bemnifosbuvir (BEM), AT-527 | Atea Pharmaceuticals, Inc. | Healthy Volunteer, Hepatic Impairment | 04/24 | 04/24 | | |
NCT05618314: Study of AT-527 in Subjects With Normal and Impaired Renal Function |
|
|
| Completed | 1 | 36 | Canada | AT-527, Bemnifosbuvir, AT-527 and Probenecid | Atea Pharmaceuticals, Inc. | Healthy Volunteer, Renal Impairment | 06/24 | 06/24 | | |
NCT06204679: Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir |
|
|
| Completed | 1 | 42 | US | Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions, Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions, Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions | Atea Pharmaceuticals, Inc. | Healthy Volunteer Study | 08/24 | 08/24 | | |
NCT06356194: Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir |
|
|
| Completed | 1 | 28 | Canada | Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK, Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. | Atea Pharmaceuticals, Inc. | Healthy Volunteer Study | 05/24 | 05/24 | | |
| yiqibuvir (HEC110114) / HEC Pharm |
NCT05395416: Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C |
|
|
| Recruiting | 2/3 | 520 | RoW | HEC74647PA+HEC110114, Antaitavir Hasophate+Yiqibuvir, Placebo | Sunshine Lake Pharma Co., Ltd. | Chronic HCV Infection | 04/23 | 04/23 | | |
NCT05998304: ADME Study of [14C] Yiqibuvir in Healthy Male Subjects |
|
|
| Completed | 1 | 8 | RoW | [14C] Yiqibuvir | Sunshine Lake Pharma Co., Ltd. | Healthy Male Subjects | 09/23 | 09/23 | | |
| ravidasvir/sofosbuvir (ASC18) / Ascletis |
| No trials found |
